

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	GURNEY, AUSTIN L.	Docket No.:	39766-0125 A
Serial No.:	10/697,599	Group Art Unit:	1646
Filing Date:	October 29, 2003	Examiner:	HISSONG, BRUCE D.
Customer No.	25213	Confirmation No.	7558
For:	INHIBITION OF IL-17 PRODUCTION		

FILED VIA EFS — AUGUST 2, 2007

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If Form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with M.P.E.P. §609.


This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

☐ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):

- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --
- ☐ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --
- ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- ☐ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; or
- ☐ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith;
and
- C. a fee of \$180.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ **Fee Authorization.** The Commissioner is hereby authorized to charge the above-referenced fees of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No. 39766-0125 A).

Respectfully submitted,

Dated: August 2, 2007

By: 
Ginger R. Dreger, Esq.
Reg. No. 33,055

HELLER EHRMAN LLP
Customer No. 25213
275 Middlefield Road
Menlo Park, CA 94025-3506
Telephone: (650) 324-7000
Facsimile: (650) 324-0638

CERTIFICATION


(Attachment to Information Disclosure Statement)

- ☐ 37 C.F.R. §1.97(e)(1). **APPLICANT'S UNDERSIGNED ATTORNEY HEREBY CERTIFIES THAT** each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement; or
- ☒ 37 C.F.R. §1.97(e)(2). **APPLICANT'S UNDERSIGNED ATTORNEY HEREBY CERTIFIES THAT** no item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing this certification after making reasonable inquiry, or was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement.

Respectfully submitted,

Dated: August 2, 2007

By: _____


Ginger R. Dreger, Esq.
Reg. No. 33,055

HELLER EHRMAN LLP
275 Middlefield Road
Menlo Park, CA 94025-3506
(650) 324-7000
Customer No. 25213

INFORMATION DISCLOSURE STATEMENT PTO-1449		ATTY. DOCKET NO.: 39766-0125 A		SERIAL NO.: 10/697,599			
		APPLICANT : GURNEY, AUSTIN L.					
		FILING DATE: 10/29/2003		GROUP: 1646			
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
Bowman et al., "Rationale and Safety of Anti-Interleukin-23 and Anti-Interleukin-17A Therapy", <i>Current Opinion in Infectious Diseases</i> , 19:245-252 (2006)							
Kotake et al., "IL-17 in Synovial Fluids from Patients with Rheumatoid Arthritis is a Potent Stimulator of Osteoclastogenesis", <i>Journal of Clinical Investigation</i> , 103(9):1345-1352 (1999).							
Matuskevicius et al., "Interleukin-17 mRNA Expression in Blood and CSF Mononuclear Cells in Augmented in Multiple Sclerosis", <i>Multiple Sclerosis</i> , 5(2):101-4 (1999).							
Wong et al., "Elevation of Proinflammatory Cytokine (IL-18, IL-17, IL-12) and Th2 Cytokine (IL-4) Concentrations in Patients with Systemic Lupus Erythematosus", <i>Lupus</i> 9:589-593 (2000).							
Zhang et al., "After Interleukin-12p40, are Interleukin-23 and Interleukin-17 the Next Therapeutic Targets for Inflammatory Bowel Disease?", <i>International Immunopharmacology</i> 7:409-416 (2007).							
EXAMINER			DATE CONSIDERED				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.